Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck (Q33335541)

25 July 2017

title

Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck (English)

1 reference

25 July 2017

1 reference

Grecula JC

1

1 reference

25 July 2017

Smith RE

2

1 reference

25 July 2017

Rhoades CA

3

1 reference

25 July 2017

Sharma P

4

1 reference

25 July 2017

Agrawal A

5

1 reference

25 July 2017

Zhang H

6

1 reference

25 July 2017

Allen J

7

1 reference

25 July 2017

Goldman FP

8

1 reference

25 July 2017

Young D

9

1 reference

25 July 2017

Schuller DE

10

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

25 July 2017

1 reference

25 July 2017

volume

89

1 reference

25 July 2017

issue

12

1 reference

25 July 2017

page(s)

2587-2596

1 reference

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

5-year results of cisplatin and fluorouracil infusion in head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Promotion of microtubule assembly in vitro by taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Taxol stabilizes microtubules in mouse fibroblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Cisplatin and mitoguazone. An induction chemotherapy regimen in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Induction chemotherapy in advanced head and neck cancer. A Radiation Therapy Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Intensification regimen 2 for advanced head and neck squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

The effect of antineoplastic agents on the healing of small intestinal anastomoses in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

The effect of intermittent-release intraperitoneal chemotherapy on wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001215%2989%3A12%3C2587%3A%3AAID-CNCR11%3E3.0.CO%3B2-R

10.1002/1097-0142(20001215)89:12<2587::AID-CNCR11>3.0.CO;2-R

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference